Open Access
19-03-2024 | Type 1 Diabetes | Short Communication
No association between long-chain n-3 fatty acid intake during pregnancy and risk of type 1 diabetes in offspring in two large Scandinavian pregnancy cohorts
Authors:
Nicolai A. Lund-Blix, Anne A. Bjerregaard, German Tapia, Ketil Størdal, Anne Lise Brantsæter, Marin Strøm, Thorhallur I. Halldorsson, Charlotta Granstrøm, Jannet Svensson, Geir Joner, Torild Skrivarhaug, Pål R. Njølstad, Sjurdur F. Olsen, Lars C. Stene
The aim of this study was to investigate whether higher dietary intake of marine n-3 fatty acids during pregnancy is associated with a lower risk of type 1 diabetes in children.
Methods
The Danish National Birth Cohort (DNBC) and the Norwegian Mother, Father and Child Cohort Study (MoBa) together include 153,843 mother–child pairs with prospectively collected data on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake during pregnancy from validated food frequency questionnaires. Type 1 diabetes diagnosis in children (n=634) was ascertained from national diabetes registries.
Results
There was no association between the sum of EPA and DHA intake during pregnancy and risk of type 1 diabetes in offspring (pooled HR per g/day of intake: 1.00, 95% CI 0.88, 1.14), with consistent results for both the MoBa and the DNBC. Robustness analyses gave very similar results.
Conclusions/interpretation
Initiation of a trial of EPA and DHA during pregnancy to prevent type 1 diabetes in offspring should not be prioritised.
No association between long-chain n-3 fatty acid intake during pregnancy and risk of type 1 diabetes in offspring in two large Scandinavian pregnancy cohorts
Authors
Nicolai A. Lund-Blix Anne A. Bjerregaard German Tapia Ketil Størdal Anne Lise Brantsæter Marin Strøm Thorhallur I. Halldorsson Charlotta Granstrøm Jannet Svensson Geir Joner Torild Skrivarhaug Pål R. Njølstad Sjurdur F. Olsen Lars C. Stene
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.